NEW YORK, September 22, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6643-100free.
Gilead Sciences, Inc. Research Reports
On September 15, 2014, Gilead Sciences, Inc. (Gilead) announced the signing of non-exclusive licensing agreements with seven India-based generic pharmaceutical manufacturers for expanding access to its chronic hepatitis C medicines in developing countries. According to Gilead, the agreement permits the companies - Cadila Healthcare Ltd., Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd., Ranbaxy Laboratories Ltd., Sequent Scientific Ltd. and Strides Arcolab Ltd. - to manufacture sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir for distribution in 91 developing countries. Under the licensing agreements, these companies will receive a complete technology transfer of the Gilead manufacturing process to quickly scale up production. Further, the licensees can set their own prices for the generic product produced by them, but they have to pay a royalty on sales to Gilead. Gilead stated that the countries within the agreement account for more than 100 million people living with hepatitis C, representing 54% of the total global infected population. The full research reports on Gilead are available to download free of charge at:
AbbVie Inc. Research Reports
On September 11, 2014, AbbVie Inc. (AbbVie) announced results from a Phase 3 pivotal study showing the efficacy of the Company's HUMIRA® (adalimumab) in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS) - a chronic inflammatory skin disease. According to the Company, the relevant data was presented at the 44th Annual European Society for Dermatological Research (ESDR) meeting in Copenhagen, Denmark. AbbVie notified that as per results from the PIONEER I study, moderate-to-severe HS patients treated with HUMIRA 40 mg weekly achieved a significantly greater response versus those on placebo at week 12 (41.8% versus 26%, p = 0.003). AbbVie informed that PIONEER I is a Phase 3, 36-week, multicenter, randomized, double-blind, two-period study in moderate-to-severe HS patients (n=307). AbbVie stated that currently there are no approved medications for the treatment of this disease. The full research reports on AbbVie are available to download free of charge at:
Pfizer Inc. Research Reports
On August 30, 2014, Pfizer Inc. (Pfizer), along with Bristol-Myers Squibb Company (Bristol-Myers), announced results of a pre-specified secondary analysis of the their Eliquis Phase 3 AMPLIFY-EXT trial (Apixaban after the initial Management of Pulmonary embolism and deep vein thrombosis with First-line therapy-EXTended Treatment) that evaluated clinical and demographic predictors of all-cause hospitalization in patients with Venous Thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism. Results from the analysis showed that during the 12-month extended treatment of VTE, Eliquis significantly reduced the risk of hospitalization versus placebo. The secondary analysis demonstrated that Eliquis 2.5 mg (p=0.032) and 5 mg (p=0.004) were both associated with significant reduction in all-cause hospitalization as compared with placebo. These data were presented at the ESC Congress 2014 in Barcelona, Spain. The full research reports on Pfizer are available to download free of charge at:
Auxilium Pharmaceuticals Inc. Research Reports
On September 17, 2014, Auxilium Pharmaceuticals Inc.'s (Auxilium) stock surged 44.89% to $31.18 after the Company announced that it has received an unsolicited, non-binding proposal from Endo International plc to acquire all of the outstanding shares of the Company's common stock at a price of $28.10 per share in cash and Endo stock, subject to due diligence, financing and other conditions. Further, in light of the said proposal, Auxilium announced that its Board has unanimously adopted a one-year stockholder rights plan effective September 16, 2014 and declared a dividend distribution of one preferred share purchase right on each outstanding share of Auxilium's common stock. The full research reports on Auxilium are available to download free of charge at:
Endo International plc Research Reports
On September 16, 2014, Endo International plc (Endo) announced the delivery of a proposal to acquire all of the outstanding shares of Auxilium Pharmaceuticals, Inc. in a cash and stock transaction valued at $2.2 billion. Endo stated that its proposal represents a 31% premium to the closing price of Auxilium's stock on September 16, 2014. Under the terms of the proposal, the consideration would include an approximately equal mix of cash and Endo stock. Endo plans to fund the transaction through a combination of cash and debt. Rajiv De Silva, President and CEO of Endo said, "In light of the highly complementary nature of our two companies' commercial portfolios, the growth potential of Auxilium's Xiaflex® and the significant synergy opportunities, we believe this compelling strategic combination would result in and create benefits for both Endo and Auxilium shareholders, as well as for patients, customers and employees." The full research reports on Endo are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review